Literature DB >> 18022007

Serratia marcescens isolated in 2005 from clinical specimens from patients with diminished immunity.

A Młynarczyk1, G Młynarczyk, J Pupek, A Bilewska, D Kawecki, M Łuczak, J Gozdowska, M Durlik, L Paczek, A Chmura, W Rowińnski.   

Abstract

Serratia marcescens is an important agent in hospital infections. The aim of this paper was to compare the resistance patterns of S. marcescens strains isolated during 1 year from patients of various wards of the Institute of Transplantology. The mechanisms of beta-lactam antibiotic resistance were of especial interest. We investigated the 81 strains of S. marcescens, isolated during 2005 from patients on 3 wards and 1 clinic of the Transplantation Institute. An unusually high resistance to most antibiotics was observed among S. marcescens strains. Extended spectrum beta-lactamases (ESBLs) were probably produced by 63.2% to 84.6% of strains, depending on the ward. Additionally, about 30% of them were probably derepressed AmpC producers. The patterns of resistance indicated that at least 2 resistant clones of S. marcescens spread among the patients. One of the clones demonstrated both ESBL and derepressed AmpC production and was susceptible only to carbapenems. The second, producing ESBL, was susceptible to piperacillin/tazobactam and carbapenems. All investigated strains were resistant to nitrofurantoin. Strains of the second group were rarely susceptible to other antibiotics: aminoglycosides, ciprofloxacin, cotrimoxazole, or fosfomycin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022007     DOI: 10.1016/j.transproceed.2007.08.046

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Serratia marcescens- a rare opportunistic nosocomial pathogen and measures to limit its spread in hospitalized patients.

Authors:  Ashish Khanna; Menka Khanna; Aruna Aggarwal
Journal:  J Clin Diagn Res       Date:  2012-11-22

2.  Chitoporin from Serratia marcescens: recombinant expression, purification and crystallization.

Authors:  Rawiporn Amornloetwattana; Robert C Robinson; Hannadige Sasimali Madusanka Soysa; Bert van den Berg; Wipa Suginta
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-10-29       Impact factor: 1.056

Review 3.  Serratia infections: from military experiments to current practice.

Authors:  Steven D Mahlen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

4.  Algal polysaccharide's potential to combat respiratory infections caused by Klebsiella pneumoniae and Serratia marcescens biofilms.

Authors:  Jyoti Vishwakarma; Bhumika Waghela; Berness Falcao; Sirisha L Vavilala
Journal:  Appl Biochem Biotechnol       Date:  2021-08-27       Impact factor: 2.926

5.  Genomic insights into nitrofurantoin resistance mechanisms and epidemiology in clinical Enterobacteriaceae.

Authors:  John Osei Sekyere
Journal:  Future Sci OA       Date:  2018-02-27

6.  Intravenous Drug Use: a Significant Risk Factor for Serratia Bacteremia.

Authors:  Timothy McCann; Hatem Elabd; Stephen P Blatt; Dominique M Brandt
Journal:  Ther Adv Infect Dis       Date:  2022-02-21

7.  Recent independent emergence of multiple multidrug-resistant Serratia marcescens clones within the United Kingdom and Ireland.

Authors:  Danesh Moradigaravand; Christine J Boinett; Veronique Martin; Sharon J Peacock; Julian Parkhill
Journal:  Genome Res       Date:  2016-07-18       Impact factor: 9.043

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.